The Science of Survival: How Biomimicry and Osmolytes Protect MSC Function
Decoupling Viability from Function: The Molecular Case for Osmolyte-Based Cryopreservation
Transitioning from a legacy DMSO-based protocol to a novel osmolyte system requires understanding the “physics” of the freeze. Because CellShield MSC is non-toxic, it allows for—and benefits from—a workflow that would be more complicated with DMSO.
- Optimizing the Workflow The CellShield MSC kit consists of a specific Buffer and a 2X Cryoprotective Agent (CPA). Achieving optimal results requires adhering to a few key best practices that differ from traditional methods:
- Dropwise Addition: The 2X CPA should be added slowly (1:1 ratio) to cells suspended in the buffer. This minimizes osmotic shock as the protective molecules equilibrate across the membrane.
- The Pre-Freeze Hold: Unlike DMSO, where time is of the essence to avoid toxicity, CellShield MSC utilizes a minimum 1-hour incubation hold at room temperature. This is critical for allowing the penetrating osmolytes to fully enter the cell.
- Uncapping for Oxygen: During this hold, we recommend uncapping the vials. Since the cells are metabolically active at room temperature, they require oxygen transfer to maintain health before the freeze.
- Controlled Cooling: Physics matters. We recommend a controlled rate freezing protocol rather than passive isopropanol containers, ensuring appropriate cooling rate and ice nucleation at the correct temperature.
Validated by the Industry You don’t have to take our word for it. The efficacy of CellShield MSC has been validated in the PACT/BEST Collaborative Study, a multi-center international study involving seven cell therapy laboratories. They confirmed that CellShield MSC delivered viability and recovery comparable to DMSO-based standards while maintaining identical cell surface phenotypes (CD45, CD73, CD90, CD105).
Furthermore, tests by a leading CDMO on both bone marrow and umbilical cord-derived MSCs confirmed that our solution offers comparable—and in some donors, superior—attachment efficiency and expansion potential compared to the industry standard.
The CellShield MSC Workflow: A simple, defined protocol designed for consistency.
Head-to-Head: CellShield™ outperforms competitors in overall yield (Recovery x Attachment).
External CDMO Validation: Comparable viability and superior attachment across multiple donors.
To learn more contact Greg Werchowski at Greg.Werchowski@eviabio.com
Now Available for Purchase: CellShield™ MSC is shipping now. Order the kit here: CellShield™ MSC Cryo Kit
GET THE LATEST CRYOPRESERVATION NEWS, CRYOCHATS™ INFO, AND ALL THE UPDATES.
Copyright © 2025 Evia Bio. All Rights Reserved. | Website Developed by Anchor Websites
